In a recent study, Karnes et al.[10] demonstrated that the time for PCa patients to develop systemic progression (SP) was significantly associated with TOP2A protein expression: higher 5-year SP rates were observed in patients with higher protein levels of the enzyme. This evidence concerns the gene TOP2A and posterior cortical atrophy.